Opinion|Videos|January 2, 2025
Emerging Data for Odronextamab in DLBCL
Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CMS Final Rule Ends Federal Medicaid, CHIP Funding for Youth Gender-Affirming Care
2
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
3
Employers With Claims Data Access Take More Cost Action, Survey Finds
4
OCTOPUS Trial Aims to Speed Access to Rare Sarcoma Drugs
5